Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic Acid and Mirabegron in Obesity
NCT05713799Phase 2Not yet recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-lipoic acid in obesity, insulin resistance (IR), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
alpha-lipoic acid
03
Conditions
obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT05713799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713799.